PT  - JOURNAL ARTICLE
AU  - Justin G. Peacock
AU  - Brendan O’Sullivan
AU  - Michael R. Povlow
TI  - A Case of <sup>177</sup>Lu-DOTATATE Therapy Without the Use of Antiemetics
AID  - 10.2967/jnmt.121.261996
DP  - 2021 Dec 01
TA  - Journal of Nuclear Medicine Technology
PG  - 354--355
VI  - 49
IP  - 4
4099  - http://tech.snmjournals.org/content/49/4/354.short
4100  - http://tech.snmjournals.org/content/49/4/354.full
SO  - J. Nucl. Med. Technol.2021 Dec 01; 49
AB  - Recommended 177Lu-DOTATATE treatment regimens involve prophylaxis with antiemetics to counteract the emetogenic properties of the nephroprotective amino acid solution infusion. We describe a 58-y-old woman treated with 177Lu-DOTATATE for metastatic small-bowel carcinoid, who was allergic to many classes of antiemetics. Therefore, she was treated with 177Lu-DOTATATE without antiemetic prophylaxis. She tolerated the compounded amino acid infusion of lysine and arginine, followed by 177Lu-DOTATATE, without significant nausea or any vomiting. We hypothesize that aggressive antiemetic prophylaxis may not be necessary if a 177Lu-DOTATATE patient receives compounded lysine/arginine amino acid solutions. The omission would decrease overall health-care costs and limit possible medication side effects.